129 related articles for article (PubMed ID: 19596945)
1. Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
Warm M; Kates R; Thomas A; Fischer T; Harbeck N
Anticancer Res; 2009 Jul; 29(7):2675-80. PubMed ID: 19596945
[TBL] [Abstract][Full Text] [Related]
2. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
[TBL] [Abstract][Full Text] [Related]
3. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant chemotherapy for primary breast cancer].
Li JF; Ouyang T; Wang TF; Lin BY
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):493-5. PubMed ID: 15555342
[TBL] [Abstract][Full Text] [Related]
5. Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer.
Warm M; Kates R; Grosse-Onnebrink E; Stoff-Khalili M; Hoopmann M; Mallmann P; Thomas A; Harbeck N
Anticancer Res; 2010 Oct; 30(10):4251-9. PubMed ID: 21036749
[TBL] [Abstract][Full Text] [Related]
6. Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.
Warm M; Kates R; Dick M; Thomas A; Mallmann P; Hoopmann M; Harbeck N
Oncol Rep; 2009 Mar; 21(3):777-85. PubMed ID: 19212639
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
Bottini A; Berruti A; Brizzi MP; Bersiga A; Generali D; Allevi G; Aguggini S; Bolsi G; Bonardi S; Tondelli B; Vana F; Tampellini M; Alquati P; Dogliotti L
Endocr Relat Cancer; 2005 Jun; 12(2):383-92. PubMed ID: 15947110
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological evaluation of preoperative chemotherapy with doxorubicin plus cyclophosphamide followed by paclitaxel for locally advanced breast cancer].
Miyake T; Miyahara S; Fujii K; Taniguchi M; Yamamura K; Tadokoro K; Tanimura M; Nakamura H
Gan To Kagaku Ryoho; 2009 Mar; 36(3):401-5. PubMed ID: 19295263
[TBL] [Abstract][Full Text] [Related]
9. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T; Morimoto K; Shimazu K; Kim SJ; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2009 Jun; 15(12):4234-41. PubMed ID: 19509181
[TBL] [Abstract][Full Text] [Related]
10. Good response to paclitaxel predicts high rates of pathologic complete response for breast cancer patients treated preoperatively with paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide.
Kim SJ; Taguchi T; Shimazu K; Tanji Y; Tamaki Y; Noguchi S
Oncology; 2009; 77(2):134-9. PubMed ID: 19628951
[TBL] [Abstract][Full Text] [Related]
11. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
[TBL] [Abstract][Full Text] [Related]
12. [The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression in breast carcinoma].
Wang S; Zhang JQ; Qiao XM; Yang DQ; Tong FZ; Liu HJ
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):1011-3. PubMed ID: 16194363
[TBL] [Abstract][Full Text] [Related]
13. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Untch M; Möbus V; Kuhn W; Muck BR; Thomssen C; Bauerfeind I; Harbeck N; Werner C; Lebeau A; Schneeweiss A; Kahlert S; von Koch F; Petry KU; Wallwiener D; Kreienberg R; Albert US; Lück HJ; Hinke A; Jänicke F; Konecny GE
J Clin Oncol; 2009 Jun; 27(18):2938-45. PubMed ID: 19364964
[TBL] [Abstract][Full Text] [Related]
14. Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
Wheeler DW; Liew TV; Bailey AR
Anaesthesia; 2007 Feb; 62(2):186-9. PubMed ID: 17223814
[TBL] [Abstract][Full Text] [Related]
15. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
16. [Practice and consideration on neoadjuvant therapy for early breast cancer].
Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):555-7. PubMed ID: 21029704
[No Abstract] [Full Text] [Related]
17. [Safety and efficacy of weekly paclitaxel followed by FEC100 as primary systemic therapy for breast cancer].
Naito K; Oura S; Yoshimasu T; Tamaki T; Ohta F; Nakamura R; Shimizu Y; Kiyoi M; Hirai Y; Miyasaka M; Okamura Y
Gan To Kagaku Ryoho; 2009 Feb; 36(2):251-4. PubMed ID: 19223740
[TBL] [Abstract][Full Text] [Related]
18. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
19. Changes in tumour biological markers during primary systemic chemotherapy (PST).
Neubauer H; Gall C; Vogel U; Hornung R; Wallwiener D; Solomayer E; Fehm T
Anticancer Res; 2008; 28(3B):1797-804. PubMed ID: 18630463
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
